VivaCT 40 Scanner
VivaCT 40 扫描仪
基本信息
- 批准号:8052441
- 负责人:
- 金额:$ 39.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-15 至 2012-04-14
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): We are requesting funding for an In Vivo micro-computerized tomography (<CT) system from SCANCO Medical (Viva-CT 40) to be sited in the barrier animal facility at the Harvard School of Public Health (HSPH) for use by the biomedical research community at HSPH and the Harvard School of Dental Medicine (HSDM) in Boston. This system consists of the Viva-CT 40 scanner, two computers for data acquisition and analysis, and an isoflurane based anesthesia system. The In Vivo <CT will be primarily used to evaluate genetically engineered mice in established and developmental models of bone loss and accrual as well as arthritis. Bone and joints are remarkable biomaterials that model and remodel to grow, preserve structural integrity and adapt to stress. This dynamic process is controlled by bone forming osteoblasts, bone resorbing osteoclasts and cartilage matrix secreting chondrocytes. An imbalance between catabolic and anabolic activity within bone and joints contributes to some of the most common public health problems including osteoporosis, arthritis and cancer. Much has been learned about the molecular control of bone remodeling by the analysis of genetically engineered mouse models of these human conditions. Importantly, humans and rodents share the majority of pathways that control osteoblast, osteoclast and chondrocyte behavior. The relatively recent availability of In Vivo <CT machines has made it possible for biologists interested in the skeletal system to follow skeletal parameters in the same mouse over time. This technique could vastly improve the quality of the currently funded studies from the major (Glimcher, Olsen and Baron) and minor (Hotamisligil, Aliprantis, Jones, Lankse, and Li) users included in this proposal who each use mouse genetics to probe the skeletal system. The Viva CT 40 will be incorporated into the existing <CT facility at HSDM where we now routinely perform Ex Vivo <CT. A strong commitment from the administration at HSPH completes this application by assuring a long- term service contract for the instrument as well as support for technical assistance. In summary, the Viva CT 40 will allow us to longitudinally compare bone parameters in the same mouse over time thereby substantially reducing the number of animals needed for robust validation of preclinical studies and facilitating the timely completion of our PHS funded projects.
Public Health Relevance: Ten faculty members at HSPH and HSDM who each use mouse genetics to probe the skeletal system are requesting funding for an In Vivo CAT scan system from SCANCO Medical (Viva-CT 40). This instrument allows the evaluation of individual genetically engineered mice in models of bone loss and accrual over time and will provide robust validation of preclinical models of human skeletal diseases such as osteoporosis and arthritis.
描述(由申请人提供):我们要求为来自Scanco Medical(Viva-CT 40)的体内微型计算机(<ct)系统提供资金,该系统位于哈佛大学公共卫生学院(HSPH)的障碍动物设施中,供HSPH和Host of Dentals Medicine in Dental(Hsphardical School)使用Biomedical Research Community(HSPH)。该系统由Viva-CT 40扫描仪,两台用于数据采集和分析的计算机以及一个基于异氟烷的麻醉系统组成。体内将主要用于评估骨质流失和应计和关节炎的建立和发展模型中的基因工程小鼠。骨骼和关节是显着的生物材料,可以模拟和重塑以生长,保持结构完整性并适应压力。这种动态过程由骨形成骨细胞,骨分辨破骨细胞和软骨基质分泌的软骨细胞控制。骨骼和关节内分解代谢和合成代谢活性之间的失衡导致了一些最常见的公共卫生问题,包括骨质疏松症,关节炎和癌症。通过分析这些人类条件的基因工程小鼠模型的分析,已经了解了骨重塑的分子控制。重要的是,人类和啮齿动物共享控制成骨细胞,破骨细胞和软骨细胞行为的大多数途径。体内机中相对较新的可用性使对骨骼系统感兴趣的生物学家可以随着时间的推移跟随同一鼠标中的骨骼参数。这项技术可以大大提高主要(Glimcher,Olsen和Baron)和Minor(Hotamisligil,apiprantis,jones,Jones,Lankse和Li)的目前资助研究的质量,其中包括本提案中的用户,他们每个人都使用小鼠遗传学来探测骨骼系统。 Viva CT 40将被合并到HSDM的现有<ct设施中,现在我们常规地执行vivo <ct。 HSPH政府的强大承诺通过确保该工具的长期服务合同以及支持技术援助来完成此申请。总而言之,VIVA CT 40将使我们能够随着时间的推移比较同一小鼠中的骨参数,从而大大减少了临床前研究验证所需的动物数量,并促进了我们的PHS资助项目的及时完成。
公共卫生相关性:HSPH和HSDM的十名教职员工使用鼠标探测骨骼系统的人正在向Scanco Medical(Viva-CT 40)提供资金用于体内CAT扫描系统。该仪器允许评估单个基因工程小鼠随着时间的流失和应计模型的评估,并将对人类骨骼疾病(例如骨质疏松症和关节炎)的临床前模型进行强有力的验证。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
LAURIE Hollis GLIM...的其他基金
Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer
制定实施社会风险转诊的实用指南:关爱健康中心 (CHC) 与癌症实施科学中心之间的合作伙伴关系
- 批准号:1082214110822141
- 财政年份:2023
- 资助金额:$ 39.67万$ 39.67万
- 项目类别:
Understanding the impact of an EHR-integrated hereditary cancer risk assessment application on patient-provider communication
了解 EHR 集成遗传性癌症风险评估应用程序对患者与提供者沟通的影响
- 批准号:1083116710831167
- 财政年份:2023
- 资助金额:$ 39.67万$ 39.67万
- 项目类别:
Real-World Molecularly Targeted Treatment Registry (MaTTeR): a Pilot Study to Enrich CCDI Data Utilizing Directed Electronic Medical Record (EMR) Extraction
真实世界分子靶向治疗登记处 (MaTTeR):利用定向电子病历 (EMR) 提取丰富 CCDI 数据的试点研究
- 批准号:1087838410878384
- 财政年份:2023
- 资助金额:$ 39.67万$ 39.67万
- 项目类别:
Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)
重新利用布鲁顿酪氨酸激酶 (BTK) 抑制剂来逆转高级别浆液性卵巢癌 (HGSC) 的免疫抑制
- 批准号:1066182310661823
- 财政年份:2022
- 资助金额:$ 39.67万$ 39.67万
- 项目类别:
Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)
重新利用布鲁顿酪氨酸激酶 (BTK) 抑制剂来逆转高级别浆液性卵巢癌 (HGSC) 的免疫抑制
- 批准号:1051244110512441
- 财政年份:2022
- 资助金额:$ 39.67万$ 39.67万
- 项目类别:
Multi-faceted Roles of an Atypical Kinase RIOK2 in Erythropoiesis and Myelodyplastic Syndromes
非典型激酶 RIOK2 在红细胞生成和骨髓增生异常综合征中的多方面作用
- 批准号:1004693010046930
- 财政年份:2020
- 资助金额:$ 39.67万$ 39.67万
- 项目类别:
Novel Regulators of Bone Formation
骨形成的新型调节剂
- 批准号:85734848573484
- 财政年份:2012
- 资助金额:$ 39.67万$ 39.67万
- 项目类别:
Schnurri-3 Inhibitors: specific inducers of adult bone formation
Schnurri-3 抑制剂:成人骨形成的特异性诱导剂
- 批准号:82597138259713
- 财政年份:2011
- 资助金额:$ 39.67万$ 39.67万
- 项目类别:
Schnurri-3 Inhibitors: specific inducers of adult bone formation
Schnurri-3 抑制剂:成人骨形成的特异性诱导剂
- 批准号:81393688139368
- 财政年份:2011
- 资助金额:$ 39.67万$ 39.67万
- 项目类别:
From Sugar to Fat: How Transcription Factor XBP1 Regulates Hepatic Lipogenesis
从糖到脂肪:转录因子 XBP1 如何调节肝脏脂肪生成
- 批准号:83086658308665
- 财政年份:2010
- 资助金额:$ 39.67万$ 39.67万
- 项目类别: